Navigation Links
New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting
Date:4/29/2009

d, randomized, parallel-group study conducted in 156 patients with early PD on stable dose of pramipexole immediate release:

  • Patients were randomized overnight to the pramipexole once-daily, extended release or to the pramipexole immediate release formulation (2:1 ratio). Primary efficacy endpoint was the proportion of patients successfully switched (no worsening of UPDRS II+III >15 percent from baseline and no drug-related adverse event leading to withdrawal). 95.5 percent of patients completed the trial, of which 84.5 percent were successfully switched (with or without dose adaptation) to the once-daily formulation. Mean pramipexole extended release dosage increased from 2.63 to 2.75mg/d (a ratio of 1:1.05) and mean pramipexole immediate release dosage from 2.74 to 2.83mg/d (a ratio of 1:1.03); these data support a 1:1 switch from pramipexole immediate release to pramipexole extended release.

In both studies, adverse events observed in patients receiving pramipexole extended release were similar to those seen in previous studies with immediate release pramipexole.

About Parkinson's disease

Parkinson's disease is a progressive neurological disorder that affects nearly one million people in the U.S. It is the second most common chronic neurological disorder in older adults after Alzheimer's. Every nine minutes someone is diagnosed with Parkinson's disease. Symptoms include tremor, muscle rigidity, slowed motion, shuffling gait, and a loss of facial expression. The symptoms vary from individual to individual, but become more severe over time. Although promising research is being conducted, there is currently no cure for Parkinson's disease.

About pramipexole

Pramipexole dihydrochloride tablets, in an immediate release formulation, are indicated in the U.S. for the treatment of the signs and symptoms of idiopathic Parki
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
2. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
3. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
4. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
5. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
8. Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies
9. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
10. Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms
11. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 29, 2015 LifeNet Health plans to enlarge ... 2015 to more than 160 people. The ... LifeNet Health,s innovative bio-implants, which are being made more ... be served. It also is a reflection of the ... "The growth and success of LifeNet Health is a ...
(Date:5/29/2015)... British Columbia and MENLO ... -- DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ... on developing and commercializing proven cancer therapies in ... at the American Association of Cancer Research ... on the potential for its lead product candidate ...
(Date:5/29/2015)... , May 29, 2015 Educating the ... the Association for the Advancement of Wound Care ... With support from AAWC,s corporate partners, the Association ... on the AAWC website at http://aawconline.org/education-for-the-generalist/ ... care pathway with links to various CME/CEU educational ...
Breaking Medicine Technology:LifeNet Health to add more than 160 jobs in 2015 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5The Association for the Advancement of Wound Care Educates the Public 2
... Findings from an international Phase 3 clinical trial of the ... and effective at restoring continence when worn up to 12 ... 87% of users rated the ability of the device to ... study results published in the British Journal of Nursing ...
... HONG KONG, Sept. 28, 2011 /PRNewswire-Asia-FirstCall/ -- Golden ... - 801.HK; 910801.TW), China,s leading integrated healthcare enterprise, today ... ownership in its NYSE-listed affiliate, China Cord Blood Corporation ... result of which the Group now owns 40.9% of ...
Cached Medicine Technology:Vitala™ Pouchless Continence Control Device Shown to be Safe and Effective for up to 12 Hours in Phase 3 Clinical Trial 2Vitala™ Pouchless Continence Control Device Shown to be Safe and Effective for up to 12 Hours in Phase 3 Clinical Trial 3Golden Meditech Increase Stake in NYSE-listed Affiliate - China Cord Blood Corporation to 40.9% 2
(Date:5/30/2015)... the Snail ” was featured on NewsWatch as part of ... and coolest applications on the market for iOS, Android, and ... conducted the app review and shared with viewers how this ... Interactive mobile games for children have become quite popular these ... playing are doing much for their intellectual development. However, there’s ...
(Date:5/29/2015)... Displays and Exhibits’ has recently aligned with a ... hanging signs ; making what was formerly an elite ... ceiling rigging points at a usual height of 16’-20’ are ... These signs are very unique and more visible than the ... and dismantle labor and rigging the costs far outweigh the ...
(Date:5/29/2015)... What does community do? , According to ... together to plant gardens, to teach young people, to ... critical issues. Community invites everyone to help improve lives ... Community Does" was commissioned by The Denver Foundation, the ... during the foundation’s Annual Celebration in May. At just ...
(Date:5/29/2015)... Cincinnati, Ohio (PRWEB) May 29, 2015 ... Proven Experience to Cincinnati , The Department of Veterans ... John A. Gennaro as the new director of the ... of health care to more than 43,000 unique Veterans ... , With over 2,000 staff, CVAMC is a two-division ...
(Date:5/29/2015)... May 29, 2015 Dot Hill can mark one ... resident of Lake Prince Woods retirement community is the ... Virginia Beach, Virginia. , “It was great fun!”, she exclaimed. ... didn’t want me to so they thought this would be ok.” ... into a vertical wind tunnel,” she described. “I don’t remember ...
Breaking Medicine News(10 mins):Health News:An Aesthetic Game that Engages and Educates Children was Featured on NewsWatch Television 2Health News:Displays and Exhibits Announces New Hanging Sign Supplier 2Health News:What Community Does: A New Video from The Denver Foundation 2Health News:VA Healthcare System of Ohio Network Announces New Medical Center Director 2Health News:Indoor Skydiving Brings Thrills to Seniors 2
... Research shows canines can count, learn words , MONDAY, ... the beloved family dog is really a toddler with ... developmental abilities equivalent to a human 2-year-old," said dog ... canine research developments at the American Psychological Association annual ...
... , The National Comprehensive Cancer Network (NCCN) recently ... the results of the recent ERSPC trial that assessed the ... screening does save lives when performed intelligently in men at ... FORT WASHINGTON, Pa., Aug. 10 Prostate-Specific Antigen (PSA) ...
... AlphaRx Inc. (OTC BB:ALRX.OB - News), an emerging ... develop novel formulations of drugs, is pleased to ... patent in China for its topical platform technology ... The platform is an integral part of the ...
... , , NEW YORK, ... CRE ) ("Care" or the "Company"), a real estate investment and finance ... today reported financial results for the second quarter ended June 30, 2009. ... GAAP of $0.5 million, or $0.03 per basic and diluted share. ...
... ROCHESTER, N.Y., Aug. 10 Your sleeping problems might be ... (FM), and Chronic Fatigue Syndrome (CFS). But it can also be ... , , Recent studies show that chronic infection ... by Professor Mark Opp from the University of Michigan Medical School ...
... Aug. 10 /PRNewswire-Asia/ -- Chindex International, Inc.,("Chindex") (Nasdaq: ... Western,healthcare products and services in the People,s Republic of ... exclusive, multi-year distribution,agreements for China with Biotest AG and ... based in Dreieich, Germany (SDAX: BIO3), specializes in,innovative hematology ...
Cached Medicine News:Health News:Dogs and 2-Year-Olds on Same Mental Plane 2Health News:Dogs and 2-Year-Olds on Same Mental Plane 3Health News:NCCN Stresses Importance of PSA Testing in High-Risk Men 2Health News:NCCN Stresses Importance of PSA Testing in High-Risk Men 3Health News:NCCN Stresses Importance of PSA Testing in High-Risk Men 4Health News:NCCN Stresses Importance of PSA Testing in High-Risk Men 5Health News:AlphaRx Receives China Patent on Its Drug Delivery Platform 2Health News:Care Investment Trust Inc. Announces Second Quarter 2009 Results 2Health News:Care Investment Trust Inc. Announces Second Quarter 2009 Results 3Health News:Care Investment Trust Inc. Announces Second Quarter 2009 Results 4Health News:Care Investment Trust Inc. Announces Second Quarter 2009 Results 5Health News:Care Investment Trust Inc. Announces Second Quarter 2009 Results 6Health News:Care Investment Trust Inc. Announces Second Quarter 2009 Results 7Health News:Care Investment Trust Inc. Announces Second Quarter 2009 Results 8Health News:Care Investment Trust Inc. Announces Second Quarter 2009 Results 9Health News:Surprise! Better Sleep with Gene-Eden(R), an Antiviral Supplement 2Health News:Surprise! Better Sleep with Gene-Eden(R), an Antiviral Supplement 3Health News:Chindex International Announces Exclusive Distribution Agreements in China for Leading Clinical Chemistry and Aesthetic Laser Products 2Health News:Chindex International Announces Exclusive Distribution Agreements in China for Leading Clinical Chemistry and Aesthetic Laser Products 3Health News:Chindex International Announces Exclusive Distribution Agreements in China for Leading Clinical Chemistry and Aesthetic Laser Products 4
Papavero-caspar specula for trans-sphenoidal hypophysectomy....
Landolt hypophysectomie instrument, spoon, bayonet-shaped, flexible....
Fahlbusch hypophysectomie instrument, spoon, bayonet-shaped, malleable....
Cushing pituitary scoop, malleable, silver-plated....
Medicine Products: